Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
The effect of vitamin K(2) (menatetrenone) on bone turnover was investigated in postmenopausal patients with osteoporosis. A 6-month open-label, randomized prospective study was conducted in 109 patients. The control group (n = 53) received calcium aspartate (133.8 mg of elemental calcium daily), while the menatetrenone group (n = 56) received 45 mg of menatetrenone daily for 6 months. Serum and urinary levels of bone turnover markers were monitored. The serum level of undercarboxylated osteocalcin (uc-OC) was significantly lower (P < 0.001) in the menatetrenone group than in the control group (at 1 month), while there was a higher level of osteocalcin containing gamma-carboxylated glutamic acid (Gla-OC) in the menatetrenone group than the control group (P = 0.018). Significant differences of uc-OC and Gla-OC between the two groups were observed from 1 month onward. In addition, a higher level of intact osteocalcin was found in the menatetrenone group compared with the control group after 6 months (P = 0.006). Assessment of bone resorption markers showed that menatetrenone therapy was associated with significantly higher urinary N-telopeptide of type I collagen (NTX) excretion compared with the control group after 6 months, while there was no significant difference of urinary deoxypyridinoline excretion between the two groups. In conclusion, one month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin, while urinary NTX excretion was increa…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another eight RCTs (not shown in table 3), the authors cited affected trial reports to draw attention to the disparities between their own findings and those reported.66–73”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [73]
Citations
Cites
2 retracted
Ishida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Honda, Y., Kuno, H., & Oizumi, K. (1998) · Bone · doi:10.1016/s8756-3282(98)00108-2 · Cited by 77 · cited 1×
“Previous studies have suggested that the urinary excretion of NTX and DPD is decreased by vitamin K2 treatment [36] or else shows no change [26, 27, 29], and there have been no previous reports about a positive effect of menatetrenone on bone resorption markers.”
ResultRetractedOsteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366 · cited 1×
“[7–12].”
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Mortality after all major types of osteoporotic fracture in men and women: an observational study
Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926 · cited 1×
“Osteoporosis is characterized by a decrease of bone strength [1] and is a major problem for the elderly population, because it leads to an increase of fractures that impairs their quality of life [2–4] and increases mortality [5, 6].”
BackgroundEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Increased bone formation in osteocalcin-deficient mice
Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., Bonadio, J., Goldstein, S., Gundberg, C., et al. (1996) · Nature · doi:10.1038/382448a0 · Cited by 1,725 · cited 1×
“Among several bone matrix proteins, osteocalcin probably has an important role in determining bone strength, because a rapid decrease of bone stiffness after oophorectomy has been observed in osteocalcin knockout mice [ 30 ].”
BackgroundReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Vertebral Fractures and Mortality in Older Women: A Prospective Study
Kado, D. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.11.1215 · Cited by 1,039 · cited 1×
“Osteoporosis is characterized by a decrease of bone strength [1] and is a major problem for the elderly population, because it leads to an increase of fractures that impairs their quality of life [2–4] and increases mortality [5, 6].”
BackgroundOleksik, A., Lips, P., Dawson, A., Minshall, M. E., Shen, W., Cooper, C., & Kanis, J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1384 · Cited by 513 · cited 1×
“Osteoporosis is characterized by a decrease of bone strength [1] and is a major problem for the elderly population, because it leads to an increase of fractures that impairs their quality of life [2–4] and increases mortality [5, 6].”
BackgroundEffects of a ginger extract on knee pain in patients with osteoarthritis
Altman, R. D., & Marcussen, K. C. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200111)44:11<2531::aid-art433>3.0.co;2-j · Cited by 507
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.
Szulc, P., Chapuy, M. C., Meunier, P. J., & Delmas, P. D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116387 · Cited by 484 · cited 3×
“Since an increased serum level of undercarboxylated osteocalcin has been recognized as a risk factor for fracture [15, 16], prevention of fracture by vitamin K2 has been explained as being due to the carboxylation of osteocalcin, which was recently suggested to be a possible modulator of the calcium-sensing receptor f…”
BackgroundDiagnostic criteria for primary osteoporosis: year 2000 revision
Orimo, H., Hayashi, Y., Fukunaga, M., Sone, T., Fujiwara, S., Shiraki, M., Kushida, K., Miyamoto, S., Soen, S., Nishimura, J., et al. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170001 · Cited by 465 · cited 1×
“Osteoporosis was diagnosed according to the Year 2000 version of the Diagnostic Criteria for Osteoporosis published by the Japanese Society for Bone and Mineral Research [ 24 ].”
MethodSelf-citationShiraki, M., Shiraki, Y., Aoki, C., & Miura, M. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.3.515 · Cited by 408 · cited 2×
“Previous studies have suggested that the urinary excretion of NTX and DPD is decreased by vitamin K2 treatment [36] or else shows no change [26, 27 , 29], and there have been no previous reports about a positive effect of menatetrenone on bone resorption markers.”
BackgroundResultSelf-citationVergnaud, P., Garnero, P., Meunier, P. J., Bréart, G., Kamihagi, K., & Delmas, P. D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3805 · Cited by 389 · cited 1×
“In order to assess the effect of menatetrenone on osteocalcin metabolism, the serum levels of osteocalcin containing gamma carboxylated glutamic acid (Gla-OC), glutamic acid-containing osteocalcin (undercarboxylated osteocalcin, uc-OC), and intact osteocalcin (i-OC) were measured by a specific radioimmunoassay for Gla…”
MethodVitamin K2 Regulation of Bone Homeostasis Is Mediated by the Steroid and Xenobiotic Receptor SXR
Tabb, M. M., Sun, A., Zhou, C., Grün, F., Errandi, J., Romero, K., Pham, H., Inoue, S., Mallick, S., Lin, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303136200 · Cited by 387
Cockayne, S., Adamson, J., Lanham-New, S., Shearer, M. J., Gilbody, S., & Torgerson, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1256 · Cited by 361 · cited 2×
“fracture [15‐18]. A recent meta-analysis revealed that vitamin K2 therapy inhibits new vertebral fractures and possibly also reduces long bone fractures, and the data showed very high consistency [ 19 ].”
BackgroundResultIdentification of a Novel Extracellular Cation-sensing G-protein-coupled Receptor
Pi, M., Faber, P., Ekema, G., Jackson, P. D., Ting, A., Wang, N., Fontilla-Poole, M., Mays, R. W., Brunden, K. R., Harrington, J. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505186200 · Cited by 316 · cited 3×
“This receptor has a dual amino acid- and calcium-sensing ability with a different affinity to divalent cations from that of the calcium-sensing receptor and is expressed in bone cells [ 20 ].”
BackgroundInfluentialSerum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women
Szulc, P., Arlot, M., Chapuy, M.-C., Duboeuf, F., Meunier, P. J., & Dr. Delmas, P. D. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091012 · Cited by 269
Primary structure of the gamma-carboxyglutamic acid-containing protein from bovine bone.
Price, P. A., Poser, J. W., & Raman, N. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3374 · Cited by 234 · cited 1×
“Vitamin K has been recognized as a modulator of bone metabolism that acts through the gamma-carboxylation of osteocalcin, which is the most abundant bone-specific noncollagenous protein in the skeleton [ 14 ].”
BackgroundKnapen, M. H. J., Schurgers, L. J., & Vermeer, C. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0337-9 · Cited by 232 · cited 2×
“Previous studies have suggested that the urinary excretion of NTX and DPD is decreased by vitamin K2 treatment [36] or else shows no change [26, 27, 29], and there have been no previous reports about a positive effect of menatetrenone on bone resorption markers.”
BackgroundResultIchikawa, T., Horie-Inoue, K., Ikeda, K., Blumberg, B., & Inoue, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600896200 · Cited by 227 · cited 2×
“Recent advances in vitamin research have revealed that vitamin K2 binds specifically to the steroid and xenobiotic receptor in osteoblastic cells [21], after which it activates the expression of genes for bone morphogenetic protein (BMP)-binding protein (Tsukushi) [22], CD-14, and collagen assembly protein (Matrilin)…”
BackgroundHodsman, A. B., Hanley, D. A., Ettinger, M. P., Bolognese, M. A., Fox, J., Metcalfe, A. J., & Lindsay, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030768 · Cited by 205 · cited 1×
“Parathyroid hormone, a typical agent of this class, increases bone formation more than it increases bone resorption, leading to improvement of bone mass and bone architecture along with a reduced incidence of fractures [13].”
BackgroundEpidemiology of vertebral osteoporosis
KANIS, J. (1992) · Bone · doi:10.1016/8756-3282(92)90189-4 · Cited by 190 · cited 1×
“Osteoporosis is characterized by a decrease of bone strength [1] and is a major problem for the elderly population, because it leads to an increase of fractures that impairs their quality of life [2–4] and increases mortality [5, 6].”
BackgroundELECTROCHEMICAL DETECTION OF DEPRESSED CIRCULATING LEVELS OF VITAMIN K1IN OSTEOPOROSIS
HART, J. P., SHEARER, M. J., KLENERMAN, L., CATTERALL, A., REEVE, J., SAMBROOK, P. N., DODOS, R. A., BITENSKY, L., & CHAYEN, J. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-6-1268 · Cited by 165 · cited 1×
“fracture [15–18].”
Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women
Plantalech, L., Guillaumont, M., Vergnaud, P., Leclercq, M., & Dr. Delmas, P. D. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650061111 · Cited by 160
Hodges, S. J., Pilkington, M. J., Stamp, T. C. B., Catterall, A., Shearer, M. J., Bitensky, L., & Chayen, J. (1991) · Bone · doi:10.1016/8756-3282(91)90027-g · Cited by 143 · cited 1×
“fracture [15–18].”
Tsugawa, N., Shiraki, M., Suhara, Y., Kamao, M., Tanaka, K., & Okano, T. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.380 · Cited by 127 · cited 2×
“revealed that the vitamin K requirement for gammacarboxylation of osteocalcin was greater in older postmenopausal women than in younger women [31].”
BackgroundSelf-citationTsugawa, N., Shiraki, M., Suhara, Y., Kamao, M., Ozaki, R., Tanaka, K., & Okano, T. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0790-8 · Cited by 87 · cited 1×
“with an increased incidence of femoral neck fracture [15, 16] and vertebral fracture [32].”
BackgroundSelf-citationIwamoto, J., Takeda, T., & Ichimura, S. (2001) · Journal of Orthopaedic Science · doi:10.1007/s007760100002 · Cited by 80 · cited 1×
“Although several clinical trials of menatetrenone have shown that it prevents fractures in patients with osteoporosis [26–28], the exact mechanisms of this effect are not fully understood.”
BackgroundRoman‐Roman, S., Garcia, T., Jackson, A. M., Theilhaber, J., Rawadi, G., Connolly, T. M., Spinella-Jaegle, S., Kawai, S., Courtois, B., Bushnell, S., et al. (2003) · Bone · doi:10.1016/s8756-3282(03)00052-8 · Cited by 73 · cited 2×
“Among these, CD-14 is known to act as a coupling factor in bone remodeling [23], so it is possible that vitamin K2 also has an influence on remodeling.”
BackgroundMiki, T., Nakatsuka, K., Naka, H., Kitatani, K., Saito, S., Masaki, H., Tomiyoshi, Y., Morii, H., & Nishizawà, Y. (2003) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740300025 · Cited by 47 · cited 2×
“Previous studies have shown that menatetrenone treatment reduces the serum level of uc-OC [27, 33–35].”
BackgroundResultTime-Dependent Effects of Vitamin K2 (Menatetrenone) on Bone Metabolism in Postmenopausal Women.
OZURU, R., SUGIMOTO, T., YAMAGUCHI, T., & CHIHARA, K. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.363 · Cited by 43
Research works printed but not linked: 1
- Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619 · DOI · Paper page
Cited by
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
Villa, J. K. D., Diaz, M. A. N., Pizziolo, V. R., & Martino, H. S. D. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1211616 · Cited by 148
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
“Administration of menatetrenone would decrease the serum level of undercarboxylated osteocalcin [76].”
BackgroundVitamin K Nutrition and Bone Health
Tsugawa, N., & Shiraki, M. (2020) · Nutrients · doi:10.3390/nu12071909 · Cited by 131
“Vitamin K deficiency reduced cOC and increased ucOC, whereas vitamin K repletion recovered these abnormalities [42].”
BackgroundSelf-citationHuang, Z.-L., Wan, S., Lu, Y.-J., Ning, L., Liu, C., & Fan, S. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2989-6 · Cited by 116
Metadata
- Authors
- Shiraki, M., & Itabashi, A.
- Affiliations
- Research Institute and Practice for Involutional Diseases (JP)
- Corresponding author
- Shiraki, Masataka
- ORCID
- Shiraki, Masataka
- Venue
- Journal of Bone and Mineral Metabolism
- Published
- 2009-01-27
- Volume
- 27
- Issue
- 3
- Pages
- 333-340
- ISSN
- 0914-8779 (ISSN-L)
- 1435-5604
- OpenAlex
- W2087814901
- Cited by
- 40
- References
- 37
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 5 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 4 · 2012: 1
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Bone and Mineral Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Vitamin K Research Studies
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
- Keywords
- menatetrenone, vitamin K2, postmenopausal osteoporosis, osteocalcin, gamma-carboxylation, undercarboxylated osteocalcin, bone turnover, bone resorption, N-terminal telopeptide of type I collagen, deoxypyridinoline, calcium supplementation
- MeSH terms
- Aged, Calcium, Female, Hemostatics, Hormones, Humans, Lumbar Vertebrae, Protein Processing, Post-Translational, Time Factors, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Osteocalcin, Bone Remodeling, Treatment Outcome, Vitamin K 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.